Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
MG-262: What the Product Record Supports
2026-10-15
APExBIO describes MG-262, or Z-Leu-Leu-Leu-B(OH)2, as a reversible, cell-permeable boronic peptide acid proteasome inhibitor. Its stated mechanism links proteasome chymotryptic activity inhibition to ubiquitinated-protein accumulation and downstream cellular phenotypes, including growth arrest and apoptosis-related readouts. Because no identity-matched paper, effect sizes, sample sizes, or independent comparator data are available here, these claims should be treated as product-level evidence rather than as a validated literature record.
Ionomycin Calcium Salt: Evidence and Scope
2026-10-14
APExBIO describes Ionomycin calcium salt, SKU B5165, as a calcium ionophore that elevates intracellular Ca2+ through membrane transport, release of regulated calcium pools, and extracellular calcium entry. The listed biological observations span protein incorporation, secretion, and bladder-cancer models, but no identity-matched paper, effect sizes, sample sizes, or statistical uncertainty is available here. These findings therefore support a product-level, model-specific interpretation rather than a validated general mechanism or therapeutic claim.
Dovitinib Evidence Gaps in Kinase Comparisons
2026-10-14
Published comparisons support careful interpretation of kinase-inhibitor selectivity and target coverage, but the supplied evidence does not establish a direct head-to-head performance profile for Dovitinib (TKI-258).
PTEN mRNA and Trastuzumab Resistance: Evidence Overview
2026-10-13
A preclinical study reported that nanoparticle-mediated PTEN mRNA delivery could counter trastuzumab resistance in HER2-positive breast cancer models by restoring PTEN-associated control of PI3K/Akt signaling. The findings support a mechanistic research hypothesis, but they do not establish clinical efficacy, product equivalence, or applicability across all resistant tumors.
γH2AX as a Lens on FLASH-RT DNA Damage
2026-10-13
γ-H2AX immunofluorescence can provide a sensitive, spatial readout of DNA-damage responses, but it is not a standalone measure of double-strand-break burden, treatment efficacy, or safety. A 2026 preclinical study of EGCG nanoparticles with FLASH radiotherapy reported stronger tumor-cell damage and immune changes, while important questions about mechanism, model generalizability, and independent validation remain.
Alkaline Phosphatase Substrate Kit: Evidence Scope
2026-10-12
The Alkaline Phosphatase (AP) Substrate Test Kit, SKU K4151, is documented by APExBIO as a BCIP/NBT chromogenic product intended for visualizing alkaline phosphatase enzyme activity. Available evidence supports its stated identity and conceptual scope, but no matched peer-reviewed study or independent performance dataset was provided.
Cy5 NHS ester(Et): Documented Product Scope
2026-10-12
Cy5 NHS ester(Et) (SKU A8769) is described by APExBIO as a water-soluble fluorescent dye reagent for conceptual labeling of primary amines in proteins, peptides, and other biomolecules. The available evidence is limited to supplier documentation; no matched research paper was provided to establish performance, mechanism beyond the stated reactive-group description, or application-specific outcomes.
Tumor Exosomal ENPP1 and cGAMP Signaling
2026-10-11
A source-grounded overview of research linking ENPP1-bearing tumor exosomes with extracellular 2'3'-cGAMP degradation, reduced STING-mediated innate immune response, and altered immune-cell infiltration, with emphasis on evidence strength and applicability limits.
Remdesivir (GS-5734): Evidence and Limits
2026-10-10
Remdesivir (GS-5734) is an antiviral nucleoside analogue prodrug studied against coronaviruses, filoviruses and other RNA viruses. This overview compares mechanistic, cell-based, animal and clinical evidence, while clarifying why coronavirus and Ebola findings cannot be directly extrapolated to Nipah virus.
Indometacin Sodium: From COX Biology to Translation
2026-10-09
Indometacin Sodium is best understood as both a canonical cyclooxygenase inhibitor and a hypothesis-generating tool for studying inflammatory stroma. Evidence from human pancreatic stellate cells supports a COX-2-linked reduction in activation-associated phenotypes, while translational researchers should treat broader pathway claims, clinical relevance, and disease-modifying potential as questions requiring independent validation.
X-Gal: Molecular Biology Context and Olfactory Evidence
2026-10-09
X-Gal is a chromogenic β-galactosidase substrate central to blue-white colony screening and reporter assays. The supplied 2024 olfaction study provides a separate, mechanistic context involving iRhom2, ADAM17, olfactory receptors, and activity-dependent transcription. This overview compares what X-Gal can conceptually report with what the olfactory study actually measured, while defining evidence limits and applicability boundaries.
Sulforaphane, Oxidative Stress, and NLRP3 in Colitis
2026-10-08
A 2024 study connected sulforaphane-mediated reduction of reactive oxygen species with suppression of NLRP3 inflammasome signaling in mouse colitis and macrophage-like cells. Its main contribution is mechanistic integration across animal and cellular models, while its preclinical design limits direct conclusions about human ulcerative colitis treatment.
5-(N,N-dimethyl)-Amiloride in Translational Research
2026-10-08
A thought-leadership analysis of 5-(N,N-dimethyl)-Amiloride hydrochloride as a mechanistic probe for intracellular pH regulation, ion transport, endothelial injury, and cardiac research. The article connects NHE biology with moesin-based sepsis research while distinguishing preclinical signals from clinically established evidence.
Sorafenib and the Next Frontier in Liver Cancer Biology
2026-10-07
A mechanistic and translational perspective on Sorafenib (BAY-43-9006), its value as a cancer biology research tool, and how recent findings on cholesterol-driven mitophagy broaden research questions in hepatocellular carcinoma.
Gut Dysbiosis and α-Synuclein Pathology in Parkinson’s
2026-10-07
This mouse study connects rotenone-associated gut microbiota dysbiosis with intestinal barrier disruption, inflammation, C/EBPβ/AEP signaling, α-synuclein pathology, and motor deficits. Its microbiota-depletion and fecal-transfer comparisons provide intervention-based evidence that the gut microbiome can modify pathology in this Parkinson’s disease model, while leaving important questions about human relevance unresolved.